OmniAb Reports Significant 2025 Revenue Decline and Increased Loss, Projects 2026 Revenue Growth

summarizeSummary

OmniAb, Inc. announced a significant 29% revenue decline and increased net loss for the full year 2025, but provided 2026 guidance projecting revenue growth and continued cash burn.

check_boxKey Events

• Full Year 2025 Financial Results

  Revenue for 2025 decreased 29% year-over-year to $18.7 million, and the net loss increased to $64.8 million, or $0.57 per share.

• Fourth Quarter 2025 Performance

  Q4 2025 revenue declined 22% to $8.4 million compared to Q4 2024, with a net loss of $14.2 million, or $0.11 per share.

• 2026 Financial Guidance

  OmniAb expects 2026 revenue to be in the range of $25 million to $30 million, and projects to end the year with cash and cash equivalents between $30 million and $35 million.

• Strategic Business Updates

  The company launched OmniUltra™, a new transgenic chicken technology, and reported 107 active partners and 407 active programs as of December 31, 2025.

auto_awesomeAnalysis

OmniAb, Inc. reported a substantial 29% year-over-year revenue decrease for the full year 2025, reaching $18.7 million, alongside an increased net loss of $64.8 million. Fourth-quarter results mirrored this trend with a 22% revenue decline and a higher net loss. This poor performance is a significant negative signal regarding the company's recent operational execution. However, the company provided 2026 revenue guidance of $25 million to $30 million, indicating an expected recovery and growth from the 2025 figures. The projected year-end cash balance of $30 million to $35 million suggests continued cash burn, but the company maintains a runway. Investors should monitor the execution of the 2026 guidance and the impact of new initiatives like OmniUltra™ and partner program advancements on future revenue and profitability.